Hepatocellular carcinoma
RecruitingA study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed
- Disease:Hepatocellular carcinoma
- Substances:LenvatinibNivolumab+2
Germany- Participants:18–64 years · 65+ years
- Substances:Lenvatinib
- Sponsor:CatalYm GmbH







